GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ANG-PD · Dec 31, 2024

American National Group Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001039828-25-000010Insurance
Cash75thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.cash

$11.3B · CORE · VALID

DebtRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.gross_debt

$3.0B · OPTIONAL · NOT_ENOUGH_HISTORY

Net-income growth95thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.net_income

246.27% · CORE · VALID

Premium growth100thOwn-history percentile · N=20
Evidence method

Yoy · gp.insurance.premiums

46018.49% · CORE · VALID

Revenue growth85thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.revenue

235.09% · CORE · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History51 statesSelf-history eligible
Period transition

What moved in the state?

Cash Decreased
Previous
$13.9B
Current
$11.3B
Delta
-$2.5B
Debt Decreased
Previous
$3.0B
Current
$3.0B
Delta
-$2.0M
Earnings Growth Increased
Previous
-160.48%
Current
246.27%
Delta
406.75%
Premium Growth Increased
Previous
33321.15%
Current
46018.49%
Delta
12697.34%
Revenue Growth Decreased
Previous
651.54%
Current
235.09%
Delta
-416.45%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.